● 上市公司所处的当事人地位：被执行人。 ● 涉案的金额：借款本金及支付利息合计 110,117,937.20 元、自 2023 年 4 月 26 日至本判决确定的还款之日的利息、案件受理费、保全费等。 ● 对上市公司损益产生负面影响：截至本公告披露日，公司持有的宁夏黄 河农村商业银行股份有限公司（以下简称：黄河银行）150 万股的股份已于 2025 年 1 月 20 日过户至黄河银行名下，公司对黄河银行股权按照交易性金融资产列 报，并按照公允价值进行后续计量，最终对公司利润产生的影响将依据 2024 年 经审计的年度报告确定。 1 证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-010 宁夏中科生物科技股份有限公司 关于重大诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 截至本公告披露日，宁夏中科生物科技股份有限公司（以下简称：公司） 整体债务规模为 20.28 亿元、其中逾期债务总规模为 18.06 亿元，涉诉债务规模 为 18.35 亿元，除子公司宁夏华辉 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-009 宁夏中科生物科技股份有限公司 股票交易风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 因信永中和会计师事务所（特殊普通合伙）（以下简称：信永中和）对宁夏 中科生物科技股份有限公司（以下简称：公司）2023 年度财务报表出具了无法 表示意见的《2023 年度审计报告》，根据《上海证券交易所股票上市规则》的相 关规定，公司股票自 2024 年 4 月 30 日起已被上海证券交易所（以下简称：上交 所）实施退市风险警示，截止目前相关无法表示意见涉及的事项尚未消除。根据 《上海证券交易所股票上市规则》的相关规定，若公司 2024 年度财务会计报告 被出具保留意见、无法表示意见或否定意见的审计报告以及财务报告内部控制 被出具无法表示意见或者否定意见的审计报告，公司股票将面临被终止上市的 风险。 ● 宁夏中科生物新材料有限公司（以下简称：中科新材）于 2024 年 2 月 7 日 进入停产状态后，根据《上海证券交易所股票 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 因信永中和会计师事务所（特殊普通合伙）（以下简称：信永中和）对公司 2023 年度财务报表出具了无法表示意见的《2023 年度审计报告》，公司股票自 2024 年 4 月 30 日起已被上海证券交易所（以下简称：上交所）实施退市风险警示，截止目前相关 无法表示意见涉及的事项尚未消除。根据《上海证券交易所股票上市规则》的相关规 定，若公司 2024 年度财务会计报告被出具保留意见、无法表示意见或否定意见的审计 报告以及财务报告内部控制被出具无法表示意见或者否定意见的审计报告，公司股票 将被上交所决定终止上市，敬请广大投资者注意投资风险。 ● 子公司宁夏中科生物新材料有限公司（以下简称：中科新材）已进入重整程序并 不代表公司进入重整程序。公司目前仍处于预重整阶段，预重整能否成功存在不确定 性，如果公司预重整成功，法院将依法审查是否受理重整申请。根据《上海证券交易 所股票上市规则》第 9.4.1 条的相关规定，如法院依法裁定受理公司重整、和解和破产 清算申请，公司股 ...

Financial Projections for 2024 - The company expects a net profit attributable to shareholders for 2024 to be approximately between -650 million and -580 million CNY[3]. - The estimated operating revenue for 2024 is projected to be between 320 million and 360 million CNY[4]. - The net profit after deducting non-recurring gains and losses is expected to be between -450 million and -370 million CNY for 2024[3]. - The estimated total profit for 2024 is projected to be between -650 million and -600 million CNY[4]. - The company's net assets at the end of 2024 are expected to be approximately between 40 million and 60 million CNY[3]. Previous Year Performance - The previous year's net profit attributable to shareholders was -464.71 million CNY, with an operating revenue of 285.69 million CNY[6]. Reasons for Expected Loss - The main reasons for the expected loss include an investment loss of approximately -247 million CNY from the equity held in a bank and impairment losses of about 200 million CNY on inventory and fixed assets[7]. Delisting Risk - The company’s stock has been under delisting risk warning since April 30, 2024, due to an audit report with no opinion expressed[8]. - If the audited net assets for 2024 are negative, the company’s stock may face delisting risk[9]. Financial Data Status - The financial data provided is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the official annual report[10].

股票交易异常波动暨风险提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： 证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-004 宁夏中科生物科技股份有限公司 ● 因信永中和会计师事务所（特殊普通合伙）（以下简称：信永中和）对宁 夏中科生物科技股份有限公司（以下简称：公司）2023 年度财务报表出具了无 法表示意见的《2023 年度审计报告》，根据《上海证券交易所股票上市规则》的 相关规定，公司股票自 2024 年 4 月 30 日起已被上海证券交易所实施退市风险 警示，截止目前相关无法表示意见涉及的事项尚未消除。根据《上海证券交易所 股票上市规则》第 9.3.11 条等相关规定，若公司 2024 年度财务类、规范类的相 关情形符合前述规定，公司股票将面临被终止上市的风险。 ● 宁夏中科生物新材料有限公司（以下简称：中科新材）于 2024 年 2 月 7 日进入停产状态后，根据《上海证券交易所股票上市规则》的相关规定，公司股 票自 2024 年 4 月 8 日起已被上海证券 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-003 宁夏中科生物科技股份有限公司 股票交易风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 因信永中和会计师事务所（特殊普通合伙）（以下简称：信永中和）对宁 夏中科生物科技股份有限公司（以下简称：公司或宁科生物）2023 年度财务报 表出具了无法表示意见的《2023 年度审计报告》，根据《上海证券交易所股票 上市规则》的相关规定，公司股票自 2024 年 4 月 30 日起已被上海证券交易所 实施退市风险警示，截止目前相关无法表示意见涉及的事项尚未消除。根据 《上海证券交易所股票上市规则》第 9.3.11 条等相关规定，若公司 2024 年度财 ● 宁夏中科生物新材料有限公司（以下简称：中科新材）于 2024 年 2 月 7 日进入停产状态后，根据《上海证券交易所股票上市规则》的相关规定，公司 股票自 2024 年 4 月 8 日起已被上海证券交易所实施其他风险警示。虽然中科 新材近期已经实现复工复产，但能否实现可 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-002 宁夏中科生物科技股份有限公司 ● 因信永中和会计师事务所（特殊普通合伙）（以下简称：信永中和）对宁 夏中科生物科技股份有限公司（以下简称：公司）2023 年度财务报表出具了无 法表示意见的《2023 年度审计报告》，根据《上海证券交易所股票上市规则》的 相关规定，公司股票自 2024 年 4 月 30 日起已被上海证券交易所实施退市风险 警示，截止目前相关无法表示意见涉及的事项尚未消除。根据《上海证券交易所 股票上市规则》第 9.3.11 条等相关规定，若公司 2024 年度财务类、规范类的相 关情形符合前述规定，公司股票将面临被终止上市的风险。 ● 宁夏中科生物新材料有限公司（以下简称：中科新材）于 2024 年 2 月 7 日进入停产状态后，根据《上海证券交易所股票上市规则》的相关规定，公司股 票自 2024 年 4 月 8 日起已被上海证券交易所实施其他风险警示。虽然中科新材 近期已经实现复工复产，但能否实现可持续的正常生产经营能力，仍有不确定性。 ● 公司于 2024 年 12 月 3 日收到广东省湛江市中级人民法院发来的 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 因信永中和会计师事务所（特殊普通合伙）（以下简称：信永中和）对宁 夏中科生物科技股份有限公司（以下简称：公司）2023 年度财务报表出具了无 法表示意见的《2023 年度审计报告》，根据《上海证券交易所股票上市规则》的 相关规定，公司股票自 2024 年 4 月 30 日起已被上海证券交易所实施退市风险 警示，截止目前相关无法表示意见涉及的事项尚未消除。根据《上海证券交易所 股票上市规则》第 9.3.11 条等相关规定，若公司 2024 年度财务类、规范类的相 关情形符合前述规定，公司股票将面临被终止上市的风险。 证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-001 宁夏中科生物科技股份有限公司 股票交易风险提示公告 ● 宁夏中科生物新材料有限公司（以下简称：中科新材）于 2024 年 2 月 7 日进入停产状态后，根据《上海证券交易所股票上市规则》的相关规定，公司股 票自 2024 年 4 月 8 日起已被上海证券交易所实施其 ...

关于宁夏中科生物科技股份有限公司 前期差错更正专项说明的审核报告 XYZH/2024YCMC01B0180 宁夏中科生物科技股份有限公司 宁夏中科生物科技股份有限公司全体股东： 我们接受委托，审核了后附的宁夏中科生物科技股份有限公司（以下简称"宁科生 物"）编制的《宁夏中科生物科技股份有限公司前期会计差错更正专项说明》（以下简 称专项说明）,就此会计差错更正专项说明，截止本报告日，基于我们所能获取的审核 证据，专项说明如下： 一、管理层和治理层的责任 根据《企业会计准则第28号——会计政策、会计估计变更和差错更正》和中国证券 监督管理委员会《公开发行证券的公司信息披露编报规则第19号—财务信息的更正及相 关披露》（2018年修订）等相关规定，编制和对外披露专项说明，保证其内容真实、准 确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并提供真实、合法、完整的审 核证据是宁科生物管理层的责任。 二、注册会计师的责任 我们的责任是对宁科生物编制的专项说明中所列示的会计差错更正事项的账务处 理情况进行审核，对会计差错更正专项说明发表意见。在审核过程中，我们实施了访谈 相关人员、检查有关会计资料与文件、检查会计记录以 ...

Financial Performance - The company achieved operating revenue of CNY 10,633.75 million with a net profit of -CNY 66.03 million during the reporting period[20]. - The company’s subsidiary, Zhongke New Materials, reported a net profit of 868.24 million CNY, reflecting a decrease of 15,259.47 million CNY[7]. - Huahui Environmental reported a net profit of 10,633.75 million CNY, with a significant decrease of 66.02%[7]. - The company’s operating revenue for the first half of 2024 was ¥113,496,434.91, representing an increase of 11.28% compared to ¥101,988,352.97 in the same period last year[38]. - The net profit attributable to shareholders for the same period was -¥424,964,064.01, compared to -¥135,975,647.09 in the previous year, indicating a significant loss[38]. - The company reported a significant investment loss of -246,542,146.15 RMB in the first half of 2024, compared to a gain of 14,069,746.82 RMB in the same period of 2023[178]. - The total comprehensive income for the first half of 2024 showed a significant loss of -135,955,293.22 RMB[196]. Cash Flow and Liquidity - Cash and cash equivalents decreased by 56.74% to 10,556,188.29 CNY, primarily due to payment of goods[1]. - The net cash flow from operating activities improved to approximately -¥10.31 million, compared to -¥25.31 million in the previous year[24]. - The net cash flow from operating activities was -10,306,648.85 RMB for the first half of 2024, an improvement from -25,308,888.97 RMB in the same period of 2023[184]. - The net increase in cash and cash equivalents was -1,904,677.41 RMB, reflecting a decrease in liquidity[186]. - The company is facing challenges in maintaining positive cash flow, necessitating strategic adjustments[186]. Investments and Assets - The company confirmed the value of trading financial assets at 317,594,681.34 CNY, resulting in an investment loss of 19,166.22 million CNY due to changes in accounting methods[1]. - Long-term equity investments decreased by 91.73% to 12,990,131.78 CNY, attributed to changes in the holding of Huanghe Bank shares[1]. - The company holds a 9.50% stake in Huanghe Bank, with a cumulative fair value change of 4.07 million CNY[4]. - The company’s investment in Huanghe Bank incurred a loss of CNY 19,166.22 million due to forced execution of shares and changes in influence over the bank's operations[20]. - The company’s long-term equity investments were reported at approximately 710.4 million CNY at the end of 2023, with no new investments reported as of June 30, 2024[158]. Liabilities and Debt - The company has a total of 223,165.11 million CNY in assets under restriction, including cash, trading financial assets, and fixed assets[4]. - The company is at risk of being delisted due to an audit report that expressed an inability to provide an opinion on its 2023 financial statements, leading to a delisting risk warning effective April 30, 2024[8]. - The company has provided guarantees totaling 82,331.44 million, with no guarantees provided to shareholders or related parties[113]. - The total amount of guarantees exceeds 50% of the company's net assets, amounting to 155,227.71 million[113]. - The company is facing litigation related to overdue loans, with claims amounting to 10,940 million shares[114]. Operational Challenges - The company faces risks from macroeconomic changes, including potential impacts from US-China trade tensions and tariffs affecting its long-chain dicarboxylic acid and coal-based activated carbon exports to regions like North America and the EU[8]. - The company’s subsidiary, Zhongke New Materials, faced a temporary shutdown from February 7 to April 27, 2024, due to insufficient working capital, resulting in a revenue of CNY 868.24 million and a net loss of -CNY 15,259.47 million[20]. - The company has undergone significant management changes, including the resignation of the chairman and several independent directors, with new appointments made[31]. - The company has faced continuous net losses for three consecutive fiscal years from 2021 to 2023, leading to uncertainty regarding its ability to continue as a going concern[45]. Environmental and Compliance - The company has been recognized as a national high-tech enterprise in 2023, utilizing third-generation biological methods for large-scale production of long-chain dicarboxylic acid, which aligns with national green chemistry initiatives[12]. - The company invested nearly 400 million yuan in environmental protection facilities, including advanced technologies for waste gas and wastewater treatment[96]. - The company is listed as a key pollutant discharge unit by the Ningxia Ecological Environment Department for 2024, ensuring compliance with environmental regulations[96]. - The company has established a comprehensive emergency response system for environmental incidents, ensuring readiness to handle unexpected pollution events[98]. - The company has received no administrative penalties related to environmental issues during the reporting period[98]. Strategic Initiatives - The company plans to enhance product quality and expand its domestic market presence to mitigate risks associated with raw material price volatility and subsidy policy changes[8]. - The company aims to increase the localization rate of raw material processing and testing equipment in response to uncertainties from the US-China trade war, which is expected to boost the market share of long-chain dicarboxylic acid[12]. - The company is actively seeking partnerships with industry players possessing deep industry experience and resources for operational cooperation[102]. - The company has signed a cooperation agreement for financial assistance, receiving ¥45 million from Laiyang City Investment to support its recovery efforts[23]. Legal Issues - The company is involved in multiple lawsuits related to financial loan agreements, with a notable case where Huanghe Bank filed a lawsuit for a loan balance of 109.4 million yuan, resulting in the forced execution of 35.86 million shares to repay a principal of 105.19 million yuan[108]. - The company has received civil judgments and execution orders from various courts regarding disputes over financial loan contracts, indicating ongoing legal challenges[108]. - The company has disclosed its legal challenges in its interim reports, highlighting the importance of transparency in its financial communications[108].